McKinney, TX (PRWEB) October 30, 2013
Erchonia, the global leader in low level laser healthcare applications, today announces the company has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) to market its new XLR8 Laser for pain treatment.
Depending on the settings selected, the Erchonia XLR8 laser can provide relief of minor chronic neck and shoulder pain; reduce pain after liposuction of the thighs, hips and stomach; or reduce post-surgery pain.
The Erchonia XLR8 laser is a handheld device that uses low level laser technology to speed the recovery process by encouraging cell regeneration. The XLR8 laser is a noninvasive, safe way to manage pain—without negative side effects.
Steven Shanks, president of Erchonia comments, “The Erchonia XLR8 laser combines three FDA 510(k) market clearances into one device. With user-definable channels, an easy-to-use interface, preset protocols and a cord free design, cold laser technology is now more flexible than ever before.”
For more information on the Erchonia XLR8 laser, please visit http://www.erchonia.com.
Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years, Erchonia has been conducting research and development with the world’s leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven safe and effective through independent level 1 clinical trials. Erchonia has garnered eight FDA 510 (k) market clearances and has several other products in research and development for new applications. Currently thousands of Erchonia’s lasers are used daily to reduce body fat, eliminate pain, and treat acne. For additional information, visit http://www.erchonia.com.